Document is current
Any future updates will be listed below
-
Authors
Bell Lynum, Karimah S.
Castro, Christine F.
Zhang, Zhen
Patel, Mehul
Tohen, Mauricio
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical Development & Commercialization Inc.
Lundbeck LLC
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 11 October 2024
First Online: 27 October 2024
Declarations
:
: This was a <i>post hoc</i> analysis of data from a trial that was conducted in accordance with the International Conference of Harmonization and Good Clinical Practice consolidated guideline and approved by the relevant institutional review board (IRB), with informed consent obtained for all patients. The list of IRBs is included as a supplement.
: Not applicable.
: Karimah S. Bell Lynum is a full-time employee of Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA. Christine F. Castro is a full-time employee of Lundbeck LLC, Deerfield, IL, USA. Zhen Zhang is a full-time employee of Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA. Mehul Patel is a full-time employee of Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA. Mauricio Tohen has received honoraria or consultation fees from Abbott, AbbVie, Alkermes, AstraZeneca, Elan, Gedeon Richter, Intracellular Therapies, Johnson & Johnson, Lilly, Lundbeck, Merck, Minerva, Neurocrine Biosciences, Otsuka, Pfizer, Roche, Sunovion, and Teva. Professor Tohen was an employee at Lilly (1997–2008); his spouse was an employee at Lilly (1998–2013).
